H.C. Wainwright has increased its price target for Greenwich LifeSciences (GLSI, Financial) to $39, up from the previous $38, while maintaining a Buy rating on the company's shares. This adjustment comes in the wake of favorable outcomes from the ongoing Phase 3 FLAMINGO-01 trial. The trial focuses on GLSI-100, a treatment for breast cancer, and has demonstrated encouraging immune response results.
The recent data reinforces confidence in the potential effectiveness of GLSI-100, prompting the analyst to revise the price target. Investors have been informed of these positive developments, indicating a strong outlook for Greenwich LifeSciences as it continues to advance its treatment through the trial process.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Greenwich LifeSciences Inc (GLSI, Financial) is $38.00 with a high estimate of $38.00 and a low estimate of $38.00. The average target implies an upside of 324.58% from the current price of $8.95. More detailed estimate data can be found on the Greenwich LifeSciences Inc (GLSI) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Greenwich LifeSciences Inc's (GLSI, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
